Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,842.50p on 20-11-2026 at 18:03:42
Change 15.50p 0.85%
Buy 1,850.50p
Sell 1,849.50p
Last Trade: Unknown 4,498.00 at 1,842.50p
Day's Volume: 5,284,688
Last Close: 1,842.50p
Open: 1,837.00p
ISIN: GB00BN7SWP63
Day's Range 1,833.00p - 1,860.00p
52wk Range: 1,735.50p - 2,282.00p
Market Capitalisation: £73.86b
VWAP: 1,845.44288p
Shares in Issue: 4.01b

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 4,498 1,842.50p OTC Trade
18:03:25 - 20-Nov-26
Unknown* 4,748 1,842.50p OTC Trade
18:03:21 - 20-Nov-26
Unknown* 7,179 1,842.50p OTC Trade
18:03:21 - 20-Nov-26
Sell* 510 1,848.00p Automatic Execution
16:25:11 - 20-Nov-26
Sell* 624 1,848.00p Automatic Execution
16:25:11 - 20-Nov-26
Sell* 63 1,848.00p Automatic Execution
16:25:11 - 20-Nov-26
Sell* 624 1,848.00p Automatic Execution
16:25:11 - 20-Nov-26
Sell* 400 1,848.00p Automatic Execution
16:25:11 - 20-Nov-26
Sell* 619 1,848.00p Automatic Execution
16:25:11 - 20-Nov-26
Sell* 400 1,848.00p Automatic Execution
16:25:11 - 20-Nov-26
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
20th Nov 2026 (Fri) 1,837.00 1,860.00 1,833.00 1,842.50 5,284,688
19th Nov 2026 (Thu) 1,858.00 1,860.50 1,820.50 1,827.00 5,186,165
18th Nov 2026 (Wed) 1,867.00 1,880.00 1,853.50 1,858.00 4,360,411
17th Nov 2026 (Tue) 1,912.50 1,916.50 1,869.00 1,869.00 7,867,220
16th Nov 2026 (Mon) 1,924.00 1,949.50 1,916.00 1,929.50 3,701,532
13th Nov 2026 (Fri) 1,897.50 1,921.00 1,892.50 1,911.50 3,100,778
12th Nov 2026 (Thu) 1,910.00 1,918.00 1,889.00 1,901.00 4,344,937
11th Nov 2026 (Wed) 1,916.50 1,918.00 1,876.00 1,887.00 3,834,027
10th Nov 2026 (Tue) 1,923.50 1,944.50 1,915.50 1,917.00 4,847,188
9th Nov 2026 (Mon) 1,885.00 1,915.50 1,885.00 1,904.50 4,196,440
6th Nov 2026 (Fri) 1,870.50 1,890.00 1,828.50 1,890.00 6,698,040
5th Nov 2026 (Thu) 1,905.00 1,915.00 1,876.00 1,890.00 5,324,484
4th Nov 2026 (Wed) 1,815.50 1,895.50 1,802.00 1,890.00 10,738,509
3rd Nov 2026 (Tue) 1,835.00 1,848.00 1,827.00 1,827.50 5,019,111
2nd Nov 2026 (Mon) 1,831.50 1,845.50 1,824.50 1,824.50 5,438,653
30th Oct 2026 (Fri) 1,838.00 1,877.00 1,830.50 1,855.00 13,549,796
29th Oct 2026 (Thu) 1,790.00 1,842.50 1,790.00 1,814.00 9,351,620
28th Oct 2026 (Wed) 1,879.50 1,879.50 1,783.50 1,831.50 16,829,097
27th Oct 2026 (Tue) 1,907.00 1,925.50 1,902.50 1,923.50 3,982,525
26th Oct 2026 (Mon) 1,903.00 1,921.50 1,898.00 1,915.00 3,085,590
23rd Oct 2026 (Fri) 1,911.50 1,911.50 1,881.00 1,894.00 5,516,426
22nd Oct 2026 (Thu) 1,875.00 1,917.00 1,863.00 1,914.00 4,466,031
21st Oct 2026 (Wed) 1,863.50 1,884.00 1,856.50 1,868.00 11,052,161
20th Oct 2026 (Tue) 1,870.00 1,879.50 1,855.00 1,868.50 5,286,220
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
19th Nov 2026 7:00 am RNS Velzatinib obtains ODD in Japan for GIST treatment
18th Nov 2026 7:00 am RNS FDA approves Nelkarmi for pretreated ALK+ NSCLC
17th Nov 2026 3:30 pm RNS Director/PDMR Shareholding
13th Nov 2026 7:00 am RNS Bexsero booster receives positive CHMP opinion
12th Nov 2026 3:30 pm RNS Director/PDMR Shareholding
6th Nov 2026 3:00 pm RNS GSK publishes provisional dividend dates
2nd Nov 2026 3:00 pm RNS Total Voting Rights
28th Oct 2026 7:00 am RNS 3rd Quarter Results
26th Oct 2026 3:30 pm RNS Director/PDMR Shareholding
26th Oct 2026 3:30 pm RNS Ris-Rez positive Ph 3 osteosarcoma data in China
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

GSK's Velzatinib granted orphan drug designation in Japan for GIST

19th Nov 2026 11:21

(Alliance News) - GSK PLC on Thursday said its investigational targeted cancer drug Velzatinib has been granted orphan drug designation in Japan for the treatment of gastrointestinal stromal tumour. Read More

IN BRIEF: GSK secures accelerated approval of Nelkarmi in US

18th Nov 2026 05:55

GSK PLC - London-based pharmaceutical company - US Food & Drug Administration grants accelerated approval to Nelkarmi, also known as neladalkib, for adults with previously-treated advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. The approval was based on trial results that confirmed an overall response rate of 49% with a duration of response of six or more months in 76% of responders and 12 plus months in 52% of responders. The approval came before the original FDA target action date of November 27 and Nelkarmi previously received FDA's breakthrough therapy and orphan drug designations. Read More

BP seeks to draw line under management turmoil with board revamp

17th Nov 2026 09:33

(Alliance News) - BP PLC announced a board refresh on Tuesday, naming the replacement for Amanda Blanc as senior independent director and bringing in two new non-executive directors, with an emphasis on oil and gas industry expertise. Read More

GSK gets support from EU panel for Meningitis B booster in adolescents

13th Nov 2026 08:37

(Alliance News) - GSK PLC on Friday said an EU advisory panel has recommended the use of Bexsero as a booster for older children who previously received the vaccine against Meningitis B. Read More

LONDON BRIEFING: Aviva on track; Landsec half-year profit jumps

13th Nov 2026 07:57

(Alliance News) - Aviva remains confident in its full-year outlook after growth in insurance premiums and wealth inflows, while Land Securities reports a sharp rise in half-year profit. GSK receives a positive European regulatory recommendation for a booster dose of its meningitis B vaccine. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value10,346.34
Change-106.34

Login to your account

Forgot Password?

Not Registered